ClinicalTrials.gg
CompletedNCT07052097Updated Feb 10, 2026

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis

A Phase 2 interventional study of TQC2938 injection and TQC2938 Placebo in Seasonal Allergic Rhinitis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Completed at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.

Enrollment
17th of 27
136 · median 160
Started
2025
with 8 others
Phase 2
12 of 27
5 open now
Registered
16th of 27
by date
Lead sponsor
1 of 27
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 17th largest by enrollment, is one of 9 that started in 2025, is one of 12 in phase 2, and was the 16th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Rhinitis, Allergic, Seasonal with a site in China, or all of them as a file.
02

Study summary

To evaluate TQC2938 injection in all patients receiving background treatment with azelastine fluticasone nasal spray. The efficacy, safety and immunogenicity of the injection in patients with seasonal allergic rhinitis compared with placebo are expected to include 136 patients.

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 75 years at the screening period
  • Patients who met the diagnostic criteria of allergic rhinitis in Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition, 2022)
  • Positive of at least 1 allergen skin prick test(SPT) and/or serum-specific IgE within 1 year before enrollment.
  • Subjects have sufficient pollen exposure during the pollen season:
  • Subjects' medical history suggested that Specific Absorption Rate (SAR) symptoms were poorly controlled or subjects' subjective symptoms were not satisfactorily controlled after drug treatment during the same pollen season in the past.
  • On the day of screening, the iTNSS score in the morning was ≥6; At baseline visit, the morning iTNSS was ≥6 points, and the average score of the past 6 rTNSS was ≥6 points;
  • During the screening/induction period, the subjects had good compliance;
  • Subjects with asthma who were assessed by the investigator or specialist as having stable asthma;
  • Voluntary participation in this trial and signing the form
  • Subjects (including partners) have no pregnancy and voluntarily take one or more non-pharmaceutical measures for at period from drug administration to 6 months after the last study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Laboratory test values did not meet the requirements during screening or randomization;
  • Any disease that the investigator believes interferes with the patient's ability to complete the entire course of the study;
  • Patients with active disease
  • People with known or suspected
  • Subjects with active or a history of malignancy;
  • History of active pulmonary tuberculosis within 12 months prior to screening;
  • Diagnosis of helminthic infection within 6 months prior to screening, not receiving standard treatment or not responding to standard treatment;
  • Subjects who have undergone nasal surgery or sinus surgery within 6 months before screening
  • Subjects have concomitant medical conditions that preclude them from completing the screening period assessment or evaluating the primary efficacy endpoint;
  • Subjects with nasal malignancies and benign tumors;
  • History of to any content of the study drugs or its
  • Subjects with a history of systemic allergy to any biological agent;
  • Pregnant or lactating women;
  • Alcohol, drug and known drug dependence;
  • Have a history of vital organ transplantation or hematopoietic stem cell/bone marrow transplantation;
  • Any medical or psychiatric condition that, in the investigator's judgment, puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results;
  • Any condition that the investigator or primary physician believes may not be appropriate for participating the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    TQC2938 injection

    TQC2938 injection, 4 weeks as a treatment cycle.

    Drug: TQC2938 injection

  • Placebo comparator
    TQC2938 Placebo

    TQC2938 placebo, 4 weeks as a treatment cycle.

    Drug: TQC2938 Placebo

Interventions

  • TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

  • DrugTQC2938 Placebo

    TQC2938 placebo, 4 weeks as a treatment cycle.

06

What researchers measure

Primary outcomes

  1. Retrospective nasal symptom score after 2 weeks

    Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 2 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 weeks

Secondary outcomes

  1. Retrospective nasal symptom score after 4 weeks

    Mean daily retrospective nasal symptom total score (rTNSS) changes from baseline at 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 4 weeks

  2. Retrospective nasal symptom score at 2-week and 4-week at day time

    Mean daily changes in retrospective nasal symptom total score (AM rTNSS) from baseline at 2 weeks and 4 weeks after treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  3. Retrospective nasal symptom score at 2-week and 4-week at night time

    Mean daily nightly retrospective nasal symptom total score (PM rTNSS) changes from baseline at 2 weeks and 4 weeks after treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  4. Instantaneous nasal symptom score

    Mean change of instantaneous nasal symptom total score (iTNSS) from baseline every morning before treatment for 2 weeks and 4 weeks. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  5. Retrospective nasal symptom score-Mean daily rTNSS change

    Mean daily rTNSS change from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  6. Peak Inspiratory Flow

    Mean daily changes in peak inspiratory flow from baseline at 2 weeks and 4 weeks after treatment.

    Time frame: Baseline up to 2 and 4 weeks

  7. Instantaneous nasal symptom score

    Mean change rate of iTNSS from baseline before treatment at 2 weeks and 4 weeks each morning. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  8. Instantaneous nasal single symptom score

    Mean changes from baseline in daily retrospective nasal symptom scores (runny nose, nasal congestion, nasal itchy, and sneezing) at 2 and 4 weeks of treatment. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  9. Instantaneous nasal single symptom score at day time

    Mean changes from baseline in scores of individual nasal symptoms (runny nose, nasal congestion, itchy nose, and sneezing) were reviewed daily (AM) at 2 weeks and 4 weeks of treatment. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  10. Instantaneous nasal single symptom score at night time

    Mean changes from baseline in scores of individual nasal symptoms (runny nose, nasal congestion, nasal itchy and sneezing) at night (PM) after 2 and 4 weeks of treatment. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  11. Retrospective ocular symptom score (rTOSS)

    Mean changes in daily retrospective ocular symptom score (rTOSS) from baseline at 2 and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  12. Retrospective ocular symptom score (AM rTOSS)

    Mean daily changes in retrospective ocular symptom score (AM rTOSS) from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  13. Retrospective ocular symptom score (PM rTOSS)

    Mean nightly retrospective ocular symptom score (PM rTOSS) changes from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  14. Instantaneous ocular symptom score (iTOSS)

    Mean change of instantaneous ocular symptom total score (iTOSS) from baseline every morning at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  15. Retrospective ocular symptom score ( rTOSS)

    Mean rate of change in daily rTOSS from baseline at 2 and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  16. Instantaneous ocular symptom score

    Mean change rate of iTOSS from baseline before treatment at 2 weeks and 4 weeks each morning. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 4 weeks

  17. Retrospective ocular single symptom score

    Average changes in scores of individual ocular symptoms (itchy, tearing, red eyes) at 2 and 4 weeks of treatment compared with baseline. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  18. Retrospective ocular single symptom score

    Average changes of individual ocular symptom scores (itchy, watery eyes, red eyes) compared with baseline were reviewed daily (AM) at 2 weeks and 4 weeks of treatment. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  19. Retrospective ocular single symptom score

    Average changes of individual ocular symptoms (itchy, watery eyes, red eyes) scores at night (PM) after 2 weeks of treatment and 4 weeks of treatment compared with baseline. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  20. Quality of life questionnaire

    Changes in quality of life questionnaire (RQLQ) scores from baseline for patients with allergic rhinitis after 2 weeks and 4 weeks of treatment. The total score is 0-168 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  21. Time of onset

    Time of onset

    Time frame: Baseline up to 4 weeks

  22. Time to Reach Maximum Plasma Concentration (Tmax)

    Curative effect peak time;

    Time frame: Baseline up to 4 weeks

  23. Area under the curve

    Area under the curve of mean daily rTNSS change from baseline at 2 and 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  24. Severity of nasal symptoms (e.g., Runny nose, nasal congestion, nasal itching, and sneezing.)

    2 weeks of treatment and 4 weeks of asymptomatic or mild symptoms (e.g., Runny nose, nasal congestion, nasal itching, and sneezing.).

    Time frame: Baseline up to 2 and 4 weeks

  25. Adverse events and serious adverse events

    Incidence and severity of adverse events (AE) and serious adverse events(SAE), and abnormal laboratory test indicators

    Time frame: Baseline up to 12 weeks

  26. Blood drug concentration

    Blood drug concentration.

    Time frame: Week 0,2, 4, 8, 12 before administration

  27. Blood eosinophil (EOS) count at each evaluation visit

    Blood eosinophil (EOS) count and percentage at each evaluation visit.

    Time frame: Week 0,2, 4, 8, 12 before administration

  28. Change from baseline in serum total immunoglobulin E (IgE) concentration

    Change and percentage change from baseline in serum total immunoglobulin E (IgE) concentration.

    Time frame: Week 0,2, 4, 8, 12 before administration

  29. The incidence of antidrug antibodies (ADA)

    The incidence and titers of antidrug antibodies (ADA) in the test subjects. If a positive result is detected for ADA in the test subjects, then the neutralizing antibody will be tested as well.

    Time frame: Week 0,2, 4, 8, 12 before administration

  30. the incidence of neutralizing antibodies (Nab)

    The incidence of neutralizing antibodies (Nab). If a positive result is detected for ADA in the test subjects, then the neutralizing antibody will be tested as well.

    Time frame: Week 0,2, 4, 8, 12 before administration

07

Study locations

30 sites
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Beijing TongRen Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
  • Ganzu Province People's Hospital
    Lanzhou, Ganzu 730000, China
  • Cangzhou central hosipital
    Cangzhou, Hebei 061000, China
  • Hebei Medical University Third Hospital
    Shijiazhuang, Hebei 050000, China
  • First Affiliated Hospital, Heilongjang University of Chinese Medigine
    Harbin, Heilongjang 150040, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450002, China
  • People'S Hospital of Zhengzhou
    Zhengzhou, Henan 450002, China
  • Zhengzhou Central Hospital
    Zhengzhou, Henan 450007, China
  • Tongji Hospital of Tongji medical college of HUST
    Wuhan, Hubei 430030, China
  • Baotou Central Hospital
    Baotou, Inner Mongolia 14000, China
  • Northern Jiangsu People'S Hospital
    Yangzhou, Jiangsu 225000, China
  • The first hospital of Jilin University
    Changchun, Jilin 130031, China
  • China-japan Friendship Hospital, Jilin University
    Changchun, Jilin 130033, China
  • Affiliated Zhongshan Hospital Of Dalian university
    Dalian, Liaoning 116001, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
    Xi'an, Shaanxi 710089, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250021, China
  • The Second People's Hospital of Shandong Province
    Jinan, Shandong 250021, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
  • Zibo Central Hospital
    Zibo, Shandong 255020, China
  • First Hospital of Shangxi Medical University
    Taiyuan, Shangxi 30001, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030000, China
  • Tianjin First Central Hospital
    Tianjin, Tianjin Municipality 300192, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830013, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Sep 2025, 1 month.

Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2025
First posted
Jul 4, 2025
StartActual
Jul 31, 2025
Primary completionActual
Sep 12, 2025
CompletionActual
Nov 28, 2025
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07052097
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Jul 31, 2025
Primary completion
Sep 12, 2025
Completion
Nov 28, 2025
Last update
Feb 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC2938

Start the discussion